1. Home
  2. MNRO vs BWAY Comparison

MNRO vs BWAY Comparison

Compare MNRO & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monro Inc.

MNRO

Monro Inc.

HOLD

Current Price

$15.64

Market Cap

528.9M

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$13.59

Market Cap

450.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNRO
BWAY
Founded
1957
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Automotive Aftermarket
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
528.9M
450.8M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
MNRO
BWAY
Price
$15.64
$13.59
Analyst Decision
Buy
Strong Buy
Analyst Count
3
2
Target Price
$17.67
$13.25
AVG Volume (30 Days)
637.0K
129.0K
Earning Date
04-28-2026
01-01-0001
Dividend Yield
7.25%
N/A
EPS Growth
N/A
N/A
EPS
0.26
N/A
Revenue
$1,195,334,000.00
N/A
Revenue This Year
N/A
$301.23
Revenue Next Year
$1.59
$24.33
P/E Ratio
$59.46
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$12.20
$7.84
52 Week High
$23.91
$26.63

Technical Indicators

Market Signals
Indicator
MNRO
BWAY
Relative Strength Index (RSI) 22.38 29.78
Support Level $13.87 $11.55
Resistance Level $17.05 $17.20
Average True Range (ATR) 0.85 1.02
MACD -0.57 -0.47
Stochastic Oscillator 5.63 15.00

Price Performance

Historical Comparison
MNRO
BWAY

About MNRO Monro Inc.

Monro Inc is an operator of retail tire and automotive repair stores in the United States. The company offers replacement tires and tire related services, automotive undercar repair services, and a broad range of routine maintenance services, on passenger cars, light trucks, and vans. It also provides other products and services for brakes; mufflers and exhaust systems; and steering, drive train, suspension, and wheel alignment.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: